Published in Blood on August 01, 1997
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer (2009) 3.45
Old, new and emerging functions of caspases. Cell Death Differ (2014) 2.01
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 1.42
Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) (2011) 1.22
Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer (2003) 1.19
Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol (2011) 1.11
Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol (1997) 1.10
BCL2 inhibits cell adhesion, spreading, and motility by enhancing actin polymerization. Cell Res (2010) 1.08
Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol (2014) 0.90
Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol (2002) 0.87
Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer (2011) 0.86
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch (2003) 0.84
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. ScientificWorldJournal (2012) 0.84
Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch (2008) 0.83
Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol (1999) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Mutation-induced protein interaction kinetics changes affect apoptotic network dynamic properties and facilitate oncogenesis. Proc Natl Acad Sci U S A (2015) 0.79
A study on evaluation of apoptosis and expression of bcl-2-related marker in wound healing of streptozotocin-induced diabetic rats. ISRN Dermatol (2013) 0.78
Genotypic and phenotypic differences between nodal and extranodal diffuse large B-Cell lymphomas. J Histochem Cytochem (2011) 0.77
Nuclei micro-array FISH, a desirable alternative for MCL diagnosis. Ann Hematol (2011) 0.77
Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing. PLoS One (2016) 0.75
Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. Biomark Insights (2007) 0.75
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet (1997) 4.27
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature (1984) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med (1990) 3.21
FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J (1991) 3.19
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (1995) 3.06
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (2001) 2.99
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn (1995) 2.83
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. Proc Natl Acad Sci U S A (1980) 2.74
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med (1993) 2.66
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci U S A (1983) 2.66
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Fibronectin is produced by human macrophages. J Exp Med (1980) 2.44
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
Increased expression of high mobility group A proteins in lung cancer. J Pathol (2006) 2.39
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol (2009) 2.35
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res (1999) 2.18
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia (2007) 2.11
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J (2000) 2.06
Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol (2001) 2.05
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 1.95
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Familial aniridia and translocation t(4;11)(q22;p13) without Wilms' tumor. Hum Genet (1983) 1.83
Aggressiveness of breast cancers found with and without screening. BMJ (1992) 1.83
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology (2001) 1.74
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (1992) 1.70
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A (2000) 1.69
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer (1999) 1.67
DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer (1998) 1.66
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood (1992) 1.65
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest (1999) 1.62